2026 年至 2032 年肝病治療市場（依肝病類型、治療類型及地區分類）

肝病治療市場評估-2026-2032

全球肝病盛行率的上升是由不良生活習慣、飲酒以及病毒性肝炎感染率上升等因素造成的。隨著這些疾病的惡化，對有效治療方法來管理和治療肝病的需求日益成長。新興國家醫療基礎設施的不斷擴大和醫療支出的不斷成長，提高了人們獲得改進的肝病治療方案和治療方法的管道，從而推動了市場擴張。預計到2024年，肝病市場規模將達到160.9億美元，到2032年將達到390.4億美元。

此外，醫學研究和技術的進步正在推動創新藥物的發展，例如靶向生技藥品和基因療法，這些藥物有可能改善治療效果並滿足肝病領域未滿足的醫療需求。預計從 2026 年到 2032 年，該市場將以約 11.72% 的複合年成長率 (CAGR) 成長。

肝病治療市場定義/概述

肝病治療包括用於管理和治療肝炎、脂肪肝、肝硬化和肝癌等肝病的療法和藥物。抗病毒藥物、免疫抑制劑和肝臟移植是可用的治療方法。它們在治療實踐中的應用包括預防疾病發作、控制症狀和提高患者的生活品質。肝病治療的未來前景光明，目前正在進行的研究重點是開發標靶治療、個人化和再生療法，以提高療效並減少副作用，最終改善全球患者的預後。

肝病盛行率的上升是否會推動肝病治療市場的發展？

肝病盛行率的上升預計將顯著推動肝病治療市場的發展。肝病包括病毒性肝炎、非酒精性脂肪肝病 (NAFLD)、酒精性肝病、肝硬化、肝癌等。根據政府最新統計數據，肝病已成為全球性健康問題。世界衛生組織 (WHO) 的數據顯示，到 2023 年，肝病每年將導致近 200 萬人死亡。

美國，美國疾病管制與預防中心（CDC）報告稱，慢性肝病和肝硬化是美國第九大死亡原因，年齡調整後的死亡率為每十萬人13.5人。

世界各國政府也積極採取措施應對日益成長的肝病盛行率。為遏止肝病的發生和發展，各國已開展了倡導改變生活方式、推行肝炎疫苗接種計畫和減少飲酒政策的公共衛生宣傳活動。這些活動對於改變監管格局和促進肝病治療的商業性成長至關重要。 2024年1月，英國國家醫療服務體系（NHS）啟動了一項全國性的肝臟健康篩檢計劃，旨在及早發現肝病，減輕醫療系統的負擔。

肝病治療市場前景光明，精準醫療和標靶治療的研究正在進行中。基因編輯和生物標記發現等生物技術創新有望改變肝病患者的治療策略，提供量身定做、更有效的解決方案。 2024年2月，史丹佛大學的研究人員在《自然》雜誌上發表了一篇開創性的論文，揭示了可以預測NAFLD進展為更嚴重肝病的基因標記。

人們對抗藥性的日益擔憂是否會阻礙肝病治療市場的成長？

肝病盛行率的不斷上升預計將推動肝病治療市場蓬勃發展。抗藥性是指病毒和細菌等微生物對用於治療的藥物產生抗藥性，從而降低現有治療的有效性。對於肝病，尤其是病毒性肝炎，B肝病毒 (HBV) 和C型肝炎病毒(HCV) 等抗藥性菌株的出現是治療的一大障礙。這些抗藥性菌株限制了治療選擇，導致治療失敗，加重病情，並增加醫療支出。

近期研究表明，肝炎病毒存在抗藥性。例如，在B肝病毒中，長期服用抗病毒藥物可能導致抗藥性突變的形成，從而降低常規用於抑制病毒複製的核苷（酸）類似物的療效。同樣，儘管目前已有用於治療丙肝的直接抗病毒藥物 (DAA)，但仍有抗藥性突變的報道，因此需要密切監測，並可能需要調整治療方法。

製藥公司和學術機構正在積極研究新型抗病毒藥物和聯合治療，以對抗抗藥性。然而，由於成本高昂且開發週期長，此類努力面臨經濟上的擔憂。此外，監管機構對安全性和有效性的證明要求嚴格，這使得新治療方法的市場准入變得複雜。

各國政府和醫療機構也積極開展預防舉措，以應對抗藥性問題，包括推廣肝炎病毒疫苗、建立早期檢測篩檢項目，以及培訓醫護人員和患者遵守治療方案。然而，應對抗藥性需要持續投入研究、監測和醫療基礎設施建設，這可能會對醫療預算和資源造成壓力。

目錄

第1章 引言

• 市場定義
• 市場區隔
• 調查方法

第2章執行摘要

• 主要發現
• 市場概覽
• 市場亮點

第3章市場概述

• 市場規模和成長潛力
• 市場趨勢
• 市場促進因素
• 市場限制
• 市場機會
• 波特五力分析

第4章 肝病治療市場（依肝病類型）

• 肝炎
• 非酒精性脂肪肝（NAFLD）
• 酒精性肝病（ALD）
• 肝硬化
• 肝癌（肝細胞癌）

第5章肝病治療市場（依治療類型）

• 藥物治療
• 肝臟移植
• 營養和生活方式干涉
• 干涉

第6章區域分析

• 北美洲
• 美國
• 加拿大
• 墨西哥
• 歐洲
• 英國
• 德國
• 法國
• 義大利
• 亞太地區
• 中國
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中東和非洲
• 南非
• 沙烏地阿拉伯
• 阿拉伯聯合大公國

第7章市場動態

• 市場促進因素
• 市場限制
• 市場機會
• COVID-19 市場影響

第8章 競爭態勢

• 主要企業
• 市場佔有率分析

第9章 公司簡介

• AbbVie Inc.
• F. Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Gilead Sciences, Inc.
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Novartis AG
• Johnson & Johnson
• Celgene Corporation
• Samsung Bioepis Co., Ltd.

第10章 市場展望與機會

• 新興技術
• 未來市場趨勢
• 投資機會

第11章 市場展望 附錄

• 簡稱列表
• 來源和參考文獻

Liver Diseases Therapeutics Market Valuation - 2026-2032

The increasing global prevalence of liver illnesses is being driven by factors such as poor lifestyles, alcohol consumption, and an increase in viral hepatitis infections. As these disorders worsen, there is a greater need for effective therapies to manage and treat liver illnesses. Expanding healthcare infrastructure and rising healthcare expenditure in emerging countries help to drive market expansion by improving access to improved treatments and therapies for liver diseases. USD 16.09 Billion in 2024 and reaching USD 39.04 Billion by 2032.

Furthermore, advances in medical research and technology are resulting in the development of innovative medicines, such as targeted biologics and gene therapies, which show promise for improving treatment results and addressing unmet medical requirements in liver disease management growth is expected to grow at a CAGR of about 11.72% from 2026-2032.

Liver Diseases Therapeutics Market: Definition/ Overview

Liver disease therapeutics include treatments and drugs for managing and curing liver illnesses such as hepatitis, fatty liver disease, cirrhosis, and liver cancer. Antiviral medications, immunosuppressants, and liver transplant procedures are among the available treatments. Their applications in therapeutic settings include avoiding disease development, controlling symptoms, and increasing patient quality of life. The future of liver disease therapeutics seems optimistic, with continuing research focusing on creating targeted medications, personalized medicine methods, and regenerative treatments that aim to improve efficacy and reduce adverse effects, ultimately improving patient outcomes worldwide.

Will Rising Prevalence of Liver Disorders Propel the Liver Diseases Therapeutics Market?

The rising prevalence of liver disorders is predicted to considerably drive the Liver disorders Therapeutics Market. Liver diseases include viral hepatitis, nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease, cirrhosis, and liver cancer. According to recent government figures, liver illnesses are becoming a major global health concern. According to the World Health Organization (WHO), liver disorders will kill nearly 2 million people annually by 2023.

In 2024, the Centers for Disease Control and Prevention (CDC) reported that chronic liver disease and cirrhosis were the ninth largest cause of death in the United States, with an age-adjusted death rate of 13.5 per 100,000 people.

Governments around the world are also taking aggressive steps to address the increased prevalence of liver ailments. To reduce the incidence and progression of liver disease, public health campaigns advocating lifestyle modifications, hepatitis virus immunization programs, and alcohol-reduction policies are being introduced. These activities are critical for changing the regulatory landscape and driving commercial growth for liver disease therapies. In January 2024, the UK's National Health Service (NHS) launched a nationwide liver health screening program, with the goal of detecting liver disorders at an earlier stage and reducing the strain on the healthcare system.

The future of the liver diseases therapeutics market appears bright, with continuous research concentrating on precision medicine methods and targeted therapeutics. Biotechnology innovations, such as gene editing techniques and biomarker discoveries, are likely to transform therapy tactics for people with liver illnesses, providing tailored and more effective solutions. Collaboration among governments, healthcare providers, and pharmaceutical companies is critical in driving progress and assuring access to quality care, ultimately improving outcomes and lowering the global burden of liver disorders. in February 2024, Stanford University researchers released a groundbreaking paper in Nature, revealing a collection of genetic markers that can predict the progression of NAFLD to more severe forms of liver disease, opening the door to tailored treatment techniques.

Will Growing Fears Regarding Drug Resistance Hamper the Growth of the Liver Diseases Therapeutics Market?

Growing prevalence of liver diseases is projected to upsurge the liver diseases therapeutics market. Drug resistance occurs when microorganisms, such as viruses or bacteria, develop resistance to the medications used to treat them, lowering the efficacy of current therapy. In the context of liver illnesses, particularly viral hepatitis, the rise of drug-resistant strains like hepatitis B virus (HBV) and hepatitis C virus (HCV) presents considerable hurdles. These resistant strains can limit treatment options and cause treatment failures, aggravating disease progression and driving up healthcare expenditures.

Recent research has demonstrated the incidence of medication resistance in hepatitis viruses. For instance, in hepatitis B, extended antiviral medication might result in the formation of resistance mutations, lowering the efficiency of nucleos(t)ide analogs routinely employed to inhibit viral reproduction. Similarly, despite the availability of direct-acting antiviral (DAA) medicines for hepatitis C, there have been reports of resistance mutations, needing close monitoring and possibly treatment regimen changes.

Pharmaceutical companies and academic organizations are aggressively researching novel antiviral medicines and combination therapies to combat medication resistance. However, the high expenses and long development schedules connected with these initiatives provide economic concerns. Furthermore, regulatory bodies have strict requirements for showing safety and efficacy, complicating the entry of new therapies to the market.

Governments and healthcare groups are also working on prevention initiatives to combat medication resistance. These include promoting hepatitis virus vaccine, creating early detection screening programs, and training healthcare practitioners and patients on treatment protocol adherence. However, combating drug resistance necessitates ongoing investment in research, surveillance, and healthcare infrastructure, which may strain healthcare budgets and resources.

Category-Wise Acumens

Will Rising Prevalence of Hepatitis Worldwide the Liver Diseases Therapeutics Market?

The increasing frequency of hepatitis worldwide is expected to have a substantial impact on the Liver Diseases Therapeutics Market. Hepatitis, particularly hepatitis B and C viruses (HBV and HCV), is still a serious global health concern, impacting millions of people. According to a WHO research, immunization, diagnostic tests, medicines, and information campaigns could avert approximately 4.5 million premature deaths in low- and middle-income countries by 2030. WHO's global hepatitis plan, which is supported by all WHO Member States, seeks to reduce new hepatitis infections by 90% and fatalities by 65% between 2016 and 2030.

Recent advancements in the pharmaceutical industry highlight substantial progress in combating hepatitis. For instance, in June 2023, AbbVie published encouraging findings from a phase 3 trial of its innovative pan-genotypic hepatitis C therapy, which demonstrated high efficacy rates across many patient populations. This study highlights ongoing attempts to improve treatment options and efficacy in battling hepatitis C, a key contributor to the liver diseases therapeutics Market.

Governments and international health organizations are also stepping up efforts to prevent hepatitis through comprehensive public health policies. The World Health Organization (WHO) has set lofty goals for ending viral hepatitis as a public health issue by 2030. These activities include increasing access to cheap diagnostic equipment, treatments, and vaccines, as well as supporting preventative measures including safe injection practices and hepatitis B vaccination programs.

Meanwhile, the most rapidly developing categories are non-alcoholic fatty liver disease (NAFLD) and its advanced version, non-alcoholic steatohepatitis (NASH). The global rise in obesity and metabolic syndrome has resulted in an increased incidence of NAFLD/NASH, which is projected to boost demand for treatments that target these disorders. Alcoholic Liver Disease (ALD), Liver Cirrhosis, and Liver Cancer (Hepatocellular Carcinoma) are also substantial market sectors, owing to developments in treatment options and increasing awareness, particularly in regions with high alcohol consumption and hepatitis prevalence.

Will Increasing Adoption of Pharmacotherapy Propel the Liver Diseases Therapeutics Market?

The growing use of pharmacotherapy is likely to boost the liver diseases therapeutics market significantly. Pharmacotherapy, which includes antivirals, immunosuppressants, and chemotherapeutic drugs, is essential in the treatment of a variety of liver illnesses, including hepatitis, non-alcoholic fatty liver disease (NAFLD), and liver cancer. In 2023 According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), pharmaceutical therapies will be used to manage more than 60% of patients with chronic liver disease. This shift is being driven by the advancement of more effective and tailored drugs that can halt disease progression, manage symptoms, and, in some cases, reverse liver damage.

Governments around the world are increasingly emphasizing healthcare investments to combat liver illnesses. In the Asia-Pacific area, governments are adopting comprehensive immunization programs and treatment measures to eradicate hepatitis and reduce disease burden, which is driving up market demand for pharmacotherapy. In March 2024, Gilead Sciences received FDA clearance for a novel combination medication for chronic hepatitis B, which is estimated to earn over $1 billion in annual sales by 2026.

Meanwhile, interventional procedures are the fastest increasing area, thanks to advances in minimally invasive approaches for treating liver tumors and cirrhosis problems such as radiofrequency ablation, transarterial chemoembolization (TACE), and selective internal radiation therapy (SIRT). These techniques offer effective therapeutic alternatives, reducing recovery periods and increasing patient outcomes, resulting in increased acceptance in clinical practice. Nutritional and lifestyle interventions, as well as liver transplantation, continue to play an important role in the market, focusing on disease prevention, management, and increasing patient survival rates.

Country/Region-wise

Will Rising Advanced Healthcare Infrastructure in North America Drive the Liver Diseases Therapeutics Market?

The growing modern healthcare infrastructure in North America is expected to drive significant growth in the liver diseases therapeutics market. The region's well-established healthcare systems, combined with significant investments in medical R&D, foster innovation and adoption of innovative therapies. Recent figures highlight North America's robust healthcare expenditure, which helps to develop and implement cutting-edge liver disease therapies.

In recent years, North America has seen significant advances in liver disease treatment. For instance, in October 2023, AbbVie announced FDA clearance for their novel hepatitis C treatment regimen, which combines two direct-acting antivirals (DAAs) with different modes of action. This approval underscores continuous efforts in the region to improve treatment efficacy and patient outcomes. Such developments profit from shipments benefit from North America's strict regulatory environment and advanced healthcare infrastructure, which allow for fast approvals and widespread uptake of new therapies.

Furthermore, the region's emphasis on precision medicine and individualized therapeutics is changing the face of liver disease therapy. For instance, in March 2024, Regeneron Pharmaceuticals reported positive Phase 3 findings for a genetically targeted medication for a subpopulation of non-alcoholic steatohepatitis (NASH) patients, with a 40% improvement in liver fibrosis compared to usual care. This news resulted in a 15% increase in the company's stock price, demonstrating the market's enthusiasm for precision methods to liver disease therapy.

Will Rising Healthcare Expenditure in Asia-Pacific Boost the Liver Diseases Therapeutics Market?

Rising healthcare expenditure in the Asia-Pacific region is predicted to significantly enhance the liver diseases therapeutics market. As Asia-Pacific economies grow, so does healthcare spending, with the goal of enhancing healthcare infrastructure, expanding access to medical services, and tackling the rising burden of chronic diseases, such as liver disease. Recent figures show significant investments in healthcare across the region, emphasizing the potential for market growth in liver disease therapies.

For instance, in recent years, countries such as China and India have seen significant rises in healthcare spending. In July 2023, China announced intentions to invest around USD 2.3 Trillion yuan (approximately USD 360 Billion USD) in healthcare reforms over the following few years, with a focus on expanding medical services and implementing innovative therapies. Similarly, India has increased healthcare investments, including steps to strengthen healthcare infrastructure and enhance access to critical drugs and treatments.

These efforts are critical in addressing Asia-Pacific's rising liver disease prevalence. Hepatitis, particularly hepatitis B and C, is a major health concern in the region. Recent company news emphasizes advances in therapy options to combat severe disorders. For instance, in September 2023, Gilead Sciences published favorable clinical trial findings for its new hepatitis C drug, which showed high efficacy and safety profiles in Asian populations. These advancements demonstrate the pharmaceutical industry's dedication to fulfilling the region's healthcare needs while also driving market growth in liver disease therapies.

Furthermore, regulatory reforms and policies that promote healthcare innovation are helping industry growth. Countries in Asia-Pacific are streamlining regulatory processes to speed up the approval and adoption of novel cures, increasing market competitiveness and promoting investment in R&D. These initiatives are intended to provide a favorable environment for pharmaceutical companies to introduce new medicines and increase their market position in liver disease therapy.

Competitive Landscape

The competitive landscape of the liver diseases therapeutics market is characterized by intense research and development activities aimed at advancing treatment options for various liver conditions. The numerous pharmaceutical companies, biotechnology firms, and academic institutions are actively involved in developing novel therapies and enhancing existing treatments. Regulatory approvals and clinical trials play a crucial role in shaping market dynamics, with companies focusing on differentiated approaches such as personalized medicine, targeted therapies, and immunomodulatory drugs to address the diverse needs of patients. Additionally, collaborations between industry players and healthcare providers contribute to the expansion of treatment options and the improvement of patient outcomes in this competitive market segment.

Some of the prominent players operating in the liver diseases therapeutics market include:

• AbbVie, Inc.
• Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Gilead Sciences, Inc.
• Bristol-Myers Squibb Company
• Pfizer, Inc.
• Novartis AG

Latest Developments

• In December 2023, Pfizer acquired Akero medicines for $7.3 billion, expanding its footprint in the liver disease medicines sector. Akero's primary candidate, efruxifermin, a FGF21 mimic used to treat NASH, has showed good results in Phase 2b trials. This acquisition demonstrates the increasing prominence of NASH in the pharmaceutical industry's pipeline.
• In November 2023, Intercept Pharmaceuticals reported 5-year follow-up results from the POISE trial of Ocaliva (obeticholic acid) in primary biliary cholangitis (PBC) at the American Association for the Study of Liver Diseases (AASLD) annual meeting. The data showed prolonged improvement in liver biochemistry and a lower risk of liver transplantation or mortality, confirming the treatment's long-term efficacy for PBC.
• In January 2024, Alnylam got FDA approval for Givlaari (givosiran), an RNAi therapy for acute hepatic porphyria. This is a substantial progress in the application of RNA interference technology to liver diseases, providing a new therapy option for a rare but severe liver condition. The approval was based on Phase 3 trial data, which revealed a 74% reduction in yearly porphyria attack rates.

Liver Diseases Therapeutics Market, By Category

• Type of Liver Disease:
• Hepatitis
• Non-alcoholic Fatty Liver Disease (NAFLD)
• Alcoholic Liver Disease (ALD)
• Liver Cirrhosis
• Liver Cancer (Hepatocellular Carcinoma)
• Type of Therapy:
• Pharmacotherapy
• Liver Transplantation
• Nutritional and Lifestyle Interventions
• Interventional Procedures
• Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Liver Diseases Therapeutics Market, By Type of Liver Disease

• Hepatitis
• Non-alcoholic Fatty Liver Disease (NAFLD)
• Alcoholic Liver Disease (ALD)
• Liver Cirrhosis
• Liver Cancer (Hepatocellular Carcinoma)

5. Liver Diseases Therapeutics Market, By Type of Therapy

• Pharmacotherapy
• Liver Transplantation
• Nutritional and Lifestyle Interventions
• Interventional Procedures

6. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

7. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

8. Competitive Landscape

• Key Players
• Market Share Analysis

9. Company Profiles

• AbbVie Inc.
• F. Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Gilead Sciences, Inc.
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Novartis AG
• Johnson & Johnson
• Celgene Corporation
• Samsung Bioepis Co., Ltd.

10. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

11. Appendix

• List of Abbreviations
• Sources and References